Weng Zhiyong, Chi Yue, Xie Jing, Liu Xuefeng, Hu Jiehua, Yang Fan, Li Lihua
Taizhou University, Department of Cell Biology, Taizhou, China.
Department of laboratory, Daqing Oil Field General Hospital, Daqing, China.
Cell Physiol Biochem. 2018;49(3):1083-1096. doi: 10.1159/000493292. Epub 2018 Sep 7.
BACKGROUND/AIMS: Clinically, biliary obstruction is often accompanied by progressive inflammation. Dehydroandrographolide (DA) possesses anti-inflammatory properties. However, the anti-inflammatory activities of DA in cholestatic liver injury remain unclear.
Mice were administered with DA by intraperitoneal injection after bile duct ligation (BDL) on day 1. Then mice were subjected to an ileocecal vein injection of lipopolysaccharide (LPS). Liver function markers, histology, pro-inflammatory cytokine levels, NF-κB activation and fibrosis formation were evaluated in BDL mice with LPS. LPS binding to primary Kupffer cells was examined by high-content cytometers.
DA was shown to greatly lower initially higher than normal levels of alanine aminotransferase (ALT) and total bilirubin (TBIL) in the serum and liver of BDL mice with LPS. DA exerted hepatic protective effects that were also confirmed by prolonged survival of BDL mice with LPS. Liver histopathology showed reduced inflammatory cellular infiltration, bile duct proliferation, and biliary necrosis with DA treatment. Furthermore, DA reduced the expression levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 in liver tissue and plasma and showed decreased NF-κB activation in BDL mice with LPS. DA could prevent LPS binding to primary Kupffer cells in the normal liver and BDL mice liver. DA also suppressed LPS-stimulated inflammatory responses by blocking the interaction between LPS and TLR4 in primary Kupffer cells and human LX-2 cells, thereby inhibiting NF-κB activation.
DA inhibition of inflammation against liver damage following BDL with LPS may be a promising agent for the treatment of cholestatic liver injury.
背景/目的:临床上,胆道梗阻常伴有进行性炎症。脱水穿心莲内酯(DA)具有抗炎特性。然而,DA在胆汁淤积性肝损伤中的抗炎活性仍不清楚。
在第1天对小鼠进行胆管结扎(BDL)后,通过腹腔注射给予DA。然后对小鼠进行回盲肠静脉注射脂多糖(LPS)。评估BDL合并LPS小鼠的肝功能指标、组织学、促炎细胞因子水平、NF-κB激活和纤维化形成。通过高内涵细胞仪检测LPS与原代库普弗细胞的结合情况。
DA可显著降低BDL合并LPS小鼠血清和肝脏中最初高于正常水平的丙氨酸转氨酶(ALT)和总胆红素(TBIL)。DA发挥了肝脏保护作用,BDL合并LPS小鼠的存活时间延长也证实了这一点。肝脏组织病理学显示,DA治疗可减少炎性细胞浸润、胆管增生和胆管坏死。此外,DA降低了BDL合并LPS小鼠肝脏组织和血浆中肿瘤坏死因子(TNF)-α和白细胞介素(IL)-6的表达水平,并显示NF-κB激活减少。DA可阻止LPS与正常肝脏和BDL小鼠肝脏中的原代库普弗细胞结合。DA还通过阻断LPS与原代库普弗细胞和人LX-2细胞中TLR4之间的相互作用,抑制LPS刺激的炎症反应,从而抑制NF-κB激活。
DA抑制BDL合并LPS后肝脏损伤的炎症反应,可能是治疗胆汁淤积性肝损伤的一种有前景的药物。